High-dose therapy for germ cell tumors
Author Information
Author(s): MPA Lyttelton, ES Newlands, C Giles, M Bower, A Guimaraes, S O'Reilly, GJS Rustin, D Samson, EJ Kanfer
Primary Institution: Imperial College School of Medicine, Hammersmith Hospitals NHS Trust, London, UK
Hypothesis
Can high-dose therapy with carboplatin adjusted for renal function improve outcomes in patients with relapsed or refractory germ cell tumors?
Conclusion
The study found that high-dose therapy is effective for a significant number of patients with primary refractory or relapsed germ cell tumors.
Supporting Evidence
- The 3-year probability of overall survival was 41%.
- The 3-year probability of disease-free survival was 28%.
- One patient died due to acute renal failure, representing 3% mortality.
Takeaway
Doctors gave strong medicine to help sick patients with a type of cancer, and many of them got better.
Methodology
Patients received high-dose therapy with autologous stem cell support and carboplatin dosage adjusted based on kidney function.
Limitations
The study was not randomized and had a small sample size.
Participant Demographics
All 31 patients were male with advanced germ cell tumors.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website